Health Canada is requesting Canadian manufacturers to temporarily discontinue distribution of Ranitidine products (common trade name: ZANTAC®) while they investigate the potential presence of an impurity called NDMA (N-nitrosodimethylamine).  NDMA is classified as a probable human carcinogen, which means long-term exposure to levels above what is considered safe could increase the risk of cancer.